Share Email Print

Proceedings Paper

IS-001: investigating a novel compound for fluorescent ureteral identification during robotic hysterectomy (Conference Presentation)
Author(s): Richard Farnam M.D.

Paper Abstract

The purpose of our study is to evaluate patient safety parameters, pharmacokinetics, and ureteral fluorescence/ease of visualization of the compound IS-001, an intravenously administered, renally cleared indigo-cyanine dye in patients undergoing robotic total laparoscopic hysterectomy using the da Vinci Xi Firefly® fluorescent imaging system. Our study design is a Phase I Open Label Case Series Trial. Our intervention is the IV administration of increasing doses (10 mg, 20mg and 40mg) of IS-001 (2mg/mL) in each eight patient cohort. Pharmacokinetic data was collected at predefined intraoperative set points and at 2, 4, and 6 hours post-op to determine maximum blood concentration, total drug exposure, and time course of excretion. Subjective surgeon assessment of ureteral fluorescence was compared to computer calculations of fluorescence intensity to evaluate ease and duration of ureteral visualization using Firefly®. IS-001 appears safe in human subjects. Pharmacokinetic data is consistent with preclinical findings in animal subjects. Subjective surgeon assessment of ureteral fluorescence indicates rapid onset of ureteral fluorescence that persists to a clinically useful degree for 30+ minutes.

Paper Details

Date Published: 14 March 2018
Proc. SPIE 10478, Molecular-Guided Surgery: Molecules, Devices, and Applications IV, 104780X (14 March 2018); doi: 10.1117/12.2291974
Show Author Affiliations
Richard Farnam M.D., Texas Urogynecology and Laser Surgery Center (United States)

Published in SPIE Proceedings Vol. 10478:
Molecular-Guided Surgery: Molecules, Devices, and Applications IV
Brian W. Pogue; Sylvain Gioux; Greg Biggs, Editor(s)

© SPIE. Terms of Use
Back to Top